|Bid||0.00 x 240300|
|Ask||1,650.00 x 53000|
|Day's Range||1,625.00 - 1,637.00|
|52 Week Range||1,242.50 - 1,653.00|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||21.53|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||0.28 (1.87%)|
|1y Target Est||18.49|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
LONDON , May 13, 2019 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the U.S. launch of the WEREWOLF™ FLOW 90 Wand with FLOW~IQ™ Technology. ...
Smith & Nephew , the global medical technology business, welcomes the launch of new medical technologies guidance from the UK National Institute for Health and Care Excellence .
Emerging markets, especially China, have been a bright spot for the company as its mature markets, including the United States which accounts for about half of its revenue, stabilise after a shaky start to last year. Growth of 15.3 percent in emerging markets powered Smith & Nephew's total revenue to $1.20 billion (£919.4 million), in line with analysts' expectations, according to a company-compiled consensus http://www.smith-nephew.com/investor-centre/reporting/analyst-consensus. Demand from emerging markets will continue to lift the company as patient populations grow and medical expertise improves, Chief Executive Officer Namal Nawana told Reuters.
Attractive stocks have exceptional fundamentals. In the case of Smith & Nephew plc (LON:SN.), there's is a notable dividend-paying company that has been able to sustain great financial health over t...
New offices for Wabtec, Smith & Nephew and SAP helped stoke new office develop in the city's urban fringe
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. F...
London firm to take new space as first tenant at Stacks at 3 Crossings for the one-time Carnegie Mellon University robotic surgery spin off it bought for $275 million.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The fourth quarter of 2018 is one of those periods, as the Russell […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Smith & Nephew plc (LON:SN.), or considering investing in the stock, you need to examin...
By Foo Yun Chee and Klaus Lauer BERLIN (Reuters) - European Union regulators are unlikely to rule by the end of March on whether a UK tax scheme for multinationals breaches EU rules on state aid, Europe's ...
LONDON , March 13, 2019 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today at the American Academy of Orthopaedic Surgeons annual meeting in Las Vegas presented ...
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. ForRead More...
The two companies enter into a strategic collaboration for future development of technology for digital surgery across a broad range of clinical areas LONDON , March 12, 2019 /PRNewswire/ -- Brainlab, ...
LONDON, March 12, 2019 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces product launches and investments that establish its multi-asset digital surgery and robotic ecosystem. "Smith & Nephew is making a long-term commitment to bring together advanced technologies in robotics, digital surgery, and machine learning as well as augmented reality to empower surgeons and improve clinical outcomes. Currently in development, NAVIO 7.0 is the next version of Smith & Nephew's handheld robotic surgical system.
The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing. The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find ...
Osiris Therapeutics, Inc. (OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursuant to which Smith & Nephew will acquire Osiris for $19.00 per share in cash, a total of approximately $660.5 million in cash. Peter Friedli, Chairman of the Board and co-founder of Osiris, said, “This is a very good outcome for Osiris’ shareholders.
First reported by the Financial Times late Friday, NuVasive shares jumped as much as 18% on the Nasdaq Stock Exchange in after-hours trading. Citing "people with direct knowledge of the talks," the Financial Times noted that discussions between the companies were ongoing and that no definitive deal had been reached. London-based Smith & Nephew produces a wide range of medical equipment and products, including "advanced wound management products" and orthopedic reconstruction devices.
NuVasive stock popped Monday on a report Smith & Nephew could be considering buying it for about $3 billion. NuVasive stock made double-digit percentage gains in high volume on the news.
European shares bounced back on Monday as new-found optimism among investors about the new round of trade talks between Beijing and Washington lifted bourses from one-week lows. Analysts cautioned that sentiment about the trade talks was volatile and that a favourable outcome was by no means a done deal. "As U.S.–Sino trade talks begin in Beijing we are once again seeing the markets adopt an all too familiar optimistic stance", wrote market City Index analyst Fiona Cincotta.